Assertio Therapeutics Overview
- Founded
-
1995
- Status
-
Public
- Employees
-
30
- Stock Symbol
-
ASRT
- Investments
-
9
- Share Price
-
$2.58
- (As of Tuesday Closing)
Assertio Therapeutics General Information
Description
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Contact Information
Website
www.assertiotx.com
Formerly Known As
Depomed, Depomed, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 100 South Saunders Road
- Suite 300
- Lake Forest, IL 60045
- United States
+1 (224) 000-0000
Assertio Therapeutics Timeline
Assertio Therapeutics Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.58 | $2.58 | $2.07 - $8.01 | $240M | 93.1M | 2.24M | $2.01 |
Assertio Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 276,318 | 210,994 | 117,243 | 91,851 |
| Revenue | 168,019 | 156,234 | 111,014 | 106,275 |
| EBITDA | 53,997 | 72,291 | 38,752 | (3,156) |
| Net Income | 97,713 | 109,625 | (1,281) | (28,144) |
| Total Assets | 405,179 | 413,913 | 326,547 | 303,274 |
| Total Debt | 38,251 | 66,873 | 73,493 | 84,102 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Assertio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Assertio Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the a
Drug Discovery
Lake Forest, IL
30
As of 2022
00000
000000000
00000
000000
e eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000 000000000
Rye Brook, NY
00
As of 0000
000.00
0000000000 0
000.00
000000
in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur
0000 000000000
Boston, MA
00
As of 0000
00000
00000000000
00000
Add Comparison
Assertio Therapeutics Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Curemark | Venture Capital-Backed | Rye Brook, NY | 00 | 000.00 | 0000000000 0 | 000.00 |
| 00000000000 | Venture Capital-Backed | Boston, MA | 00 | 00000 | 00000000000 | 00000 |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00000 | 000.00 | 0000000000 | |
| 0000000 0000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Ardsley, NY | 000 | 00000 | 000000&0 |
Assertio Therapeutics Patents
Assertio Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20140066411-A1 | Pharmaceutical compositions for extended release of azo-bonded 5-aminosalicylic acid compositions | Inactive | 28-Aug-2012 | 0000000000 | |
| US-20130316002-A1 | Compositions and methods for treating gastrointestinal motility dysfunction | Inactive | 22-May-2012 | 0000000000 | |
| CA-2850468-C | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract | Inactive | 28-Sep-2010 | 0000000000 | |
| CA-2850468-A1 | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract | Active | 28-Sep-2010 | 0000000000 | |
| EP-2621487-A2 | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract | Active | 28-Sep-2010 | A61K9/0065 |
Assertio Therapeutics Executive Team (28)
Assertio Therapeutics Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Arthur Higgins | Assertio Therapeutics | Chairman of the Board of Directors | 000 0000 |
| Daniel Peisert | Assertio Therapeutics | President, Chief Executive Officer & Director | 000 0000 |
| Heather Mason | Self | Board Member | 000 0000 |
| James Tyree | Assertio Therapeutics | Board Member | 000 0000 |
| Jeffrey Vacirca MD | Self | Board Member | 000 0000 |
Assertio Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Assertio Therapeutics Investments & Acquisitions (9)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 0000 | 31-Jul-2023 | 0000000000 | 00000 | Drug Discovery | 000000 00 |
| 0000000 00000 | 15-Dec-2021 | 000000000 | 000.00 | Buildings and Property | 000000 00 |
| 0000 0000 000 | 20-May-2020 | 0000000000 | 000.00 | Drug Delivery | 00000 000 |
| 00á0 00000000 | 07-Nov-2017 | 000000000 | 000.00 | Buildings and Property | 000000 00 |
| Janssen Pharmaceuticals (Nucynta Medical Products License Rights) | 02-Apr-2015 | Corporate Asset Purchase | 00.000 | Buildings and Property | 00000 000 |
Assertio Therapeutics Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Antares Pharma (Otrexup Injection Treatment Medicine) | Buildings and Property | Ewing, NJ | 2014 |
| 00000000 000000000 | Drug Discovery | Boston, MA | 0000 |
Assertio Therapeutics ESG
Risk Overview
Risk Rating
Updated March, 13, 2020
36.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 13,035
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 806
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 383
Rank
00.00
Percentile
Assertio Therapeutics Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 0000000000 | 02-Apr-2015 | 000000000 00000 00 | 00.000 | Completed |
|
| Depomed (Lazanda nasal spray) | 29-Jul-2013 | Corporate Asset Purchase | 000 | Completed |